Ultomiris (Ravulizumab), Handok's paroxysmal nocturnal hemoglobinuria (PNH) treatment, will be listed at ₩5,598,942 per bottle starting today (7th).

The upper limit price for Soliris (30ml) is ₩5,132,364, so if 3 vials are administered every other week, about ₩400 million won is needed for a year.

Ultomiris, on the other hand, can be administered at a maintenance dose every eight weeks from two weeks after the initial dose, which is expected to lower the annual dose per patient compared to Soliris. However, like Soliris, the pre-approval system is introduced, and health authorities check from before to after the administration.

The HIRA recently conducted